Sanctuary Advisors LLC Sells 6,069 Shares of Boston Scientific Co. (NYSE:BSX)

Sanctuary Advisors LLC trimmed its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 8.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 67,035 shares of the medical equipment provider's stock after selling 6,069 shares during the quarter. Sanctuary Advisors LLC's holdings in Boston Scientific were worth $6,033,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Boston Scientific by 4.4% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider's stock valued at $345,205,000 after acquiring an additional 173,034 shares during the period. HWG Holdings LP acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at $482,000. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Boston Scientific by 0.9% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,456,741 shares of the medical equipment provider's stock worth $289,675,000 after purchasing an additional 30,636 shares during the last quarter. Intech Investment Management LLC increased its position in shares of Boston Scientific by 153.5% during the 3rd quarter. Intech Investment Management LLC now owns 197,387 shares of the medical equipment provider's stock worth $16,541,000 after purchasing an additional 119,525 shares in the last quarter. Finally, Aigen Investment Management LP bought a new position in Boston Scientific during the 3rd quarter valued at about $567,000. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BSX has been the subject of several recent analyst reports. Barclays raised their price objective on shares of Boston Scientific from $78.00 to $86.00 and gave the stock an "overweight" rating in a report on Thursday, August 22nd. Evercore ISI lifted their price objective on Boston Scientific from $82.00 to $90.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. Truist Financial increased their target price on Boston Scientific from $90.00 to $100.00 and gave the stock a "buy" rating in a report on Monday, October 14th. Royal Bank of Canada lifted their price target on Boston Scientific from $95.00 to $98.00 and gave the company an "outperform" rating in a report on Thursday, October 24th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Boston Scientific in a report on Wednesday, November 27th. Four research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific presently has an average rating of "Moderate Buy" and an average target price of $95.52.

Boston Scientific Trading Up 0.4 %

Boston Scientific stock traded up $0.35 during midday trading on Monday, hitting $90.46. 5,541,238 shares of the stock were exchanged, compared to its average volume of 5,969,288. The stock has a market capitalization of $133.32 billion, a PE ratio of 75.02, a P/E/G ratio of 2.67 and a beta of 0.80. The company has a fifty day simple moving average of $87.98 and a two-hundred day simple moving average of $81.87. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 52 week low of $54.95 and a 52 week high of $91.93.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The company had revenue of $4.21 billion for the quarter, compared to analysts' expectations of $4.04 billion. During the same period last year, the firm posted $0.50 earnings per share. The business's quarterly revenue was up 19.3% compared to the same quarter last year. Equities research analysts anticipate that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,877 shares of the stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the completion of the sale, the director now owns 39,398 shares of the company's stock, valued at $3,610,038.74. This represents a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the company's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the transaction, the executive vice president now directly owns 29,308 shares of the company's stock, valued at approximately $2,660,580.24. The trade was a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 328,157 shares of company stock valued at $27,957,676. Company insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.